Literature DB >> 16816021

CHEK2 I157T associates with familial and sporadic colorectal cancer.

O Kilpivaara, P Alhopuro, P Vahteristo, L A Aaltonen, H Nevanlinna.   

Abstract

BACKGROUND: Recently, a functionally defective CHEK2 variant I157T has been proposed to associate with an increased risk of several types of cancer. We investigated the CHEK2 I157T variant for colorectal cancer (CRC) predisposition in a large population based study including a significant number of familial CRC cases.
METHODS: We screened the CHEK2 I157T variant in a population based series of 1042 Finnish CRC patients using restriction fragment length polymorphism. Mutation status was studied for correlation with clinical characteristics and family history of CRC and other cancers.
RESULTS: The frequency of CHEK2 I157T was significantly higher in CRC patients (7.8%, 76/972) than in healthy population controls (5.3%, 100/1885) (OR = 1.5, 95% CI 1.1 to 2.1, p = 0.008). The significant association of CHEK2 I157T with CRC was observed among patients with (10.4%, 14/135) and without (7.4%, 62/837) a family history of CRC (OR = 2.1, 95% CI 1.1 to 3.7, p = 0.01; OR = 1.4, 95% CI 1.0 to 2.0, p = 0.03; respectively). A trend towards higher variant frequency was also noted among patients with multiple primary tumours and a family history of any cancer.
CONCLUSIONS: CHEK2 I157T associates with an increased risk of CRC: the association was observed both among familial and sporadic CRC patients. Furthermore, the higher frequency of I157T among patients with multiple primary tumours as well as those with a family history of any cancer supports a role for CHEK2 I157T as a susceptibility allele for multiple cancer types.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16816021      PMCID: PMC2564563          DOI: 10.1136/jmg.2005.038331

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  23 in total

1.  Association of two mutations in the CHEK2 gene with breast cancer.

Authors:  Natalia Bogdanova; Natalia Enssen-Dubrowinskaja; Sergei Feshchenko; Gennady I Lazjuk; Yuri I Rogov; Olaf Dammann; Michael Bremer; Johann H Karstens; Christof Sohn; Thilo Dörk
Journal:  Int J Cancer       Date:  2005-08-20       Impact factor: 7.396

2.  Population-based molecular detection of hereditary nonpolyposis colorectal cancer.

Authors:  R Salovaara; A Loukola; P Kristo; H Kääriäinen; H Ahtola; M Eskelinen; N Härkönen; R Julkunen; E Kangas; S Ojala; J Tulikoura; E Valkamo; H Järvinen; J P Mecklin; L A Aaltonen; A de la Chapelle
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

3.  Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease.

Authors:  L A Aaltonen; R Salovaara; P Kristo; F Canzian; A Hemminki; P Peltomäki; R B Chadwick; H Kääriäinen; M Eskelinen; H Järvinen; J P Mecklin; A de la Chapelle
Journal:  N Engl J Med       Date:  1998-05-21       Impact factor: 91.245

4.  Characterization of tumor-associated Chk2 mutations.

Authors:  X Wu; S R Webster; J Chen
Journal:  J Biol Chem       Date:  2000-10-26       Impact factor: 5.157

5.  The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis.

Authors:  J Falck; N Mailand; R G Syljuåsen; J Bartek; J Lukas
Journal:  Nature       Date:  2001-04-12       Impact factor: 49.962

6.  Colorectal cancer and the CHEK2 1100delC mutation.

Authors:  Mirjam M de Jong; Ilja M Nolte; Gerard J Te Meerman; Winette T A van der Graaf; Marcel J Mulder; Gerrit van der Steege; Marcel Bruinenberg; Michael Schaapveld; Renée C Niessen; Maran J W Berends; Rolf H Sijmons; Robert M W Hofstra; Elisabeth G E de Vries; Jan H Kleibeuker
Journal:  Genes Chromosomes Cancer       Date:  2005-08       Impact factor: 5.006

7.  CHEK2 is a multiorgan cancer susceptibility gene.

Authors:  C Cybulski; B Górski; T Huzarski; B Masojć; M Mierzejewski; T Debniak; U Teodorczyk; T Byrski; J Gronwald; J Matyjasik; E Zlowocka; M Lenner; E Grabowska; K Nej; J Castaneda; K Medrek; A Szymańska; J Szymańska; G Kurzawski; J Suchy; O Oszurek; A Witek; S A Narod; J Lubiński
Journal:  Am J Hum Genet       Date:  2004-10-18       Impact factor: 11.025

8.  A novel founder CHEK2 mutation is associated with increased prostate cancer risk.

Authors:  Cezary Cybulski; Tomasz Huzarski; Bohdan Górski; Bartłomiej Masojć; Marek Mierzejewski; Tadeusz Debniak; Bartłomiej Gliniewicz; Joanna Matyjasik; Elzbieta Złowocka; Grzegorz Kurzawski; Andrzej Sikorski; Michał Posmyk; Marek Szwiec; Ryszard Czajka; Steven A Narod; Jan Lubiński
Journal:  Cancer Res       Date:  2004-04-15       Impact factor: 12.701

9.  CHEK2 variant I157T may be associated with increased breast cancer risk.

Authors:  Outi Kilpivaara; Pia Vahteristo; Jacob Falck; Kirsi Syrjäkoski; Hannaleena Eerola; Douglas Easton; Jirina Bartkova; Jiri Lukas; Päivi Heikkilä; Kristiina Aittomäki; Kaija Holli; Carl Blomqvist; Olli-Pekka Kallioniemi; Jiri Bartek; Heli Nevanlinna
Journal:  Int J Cancer       Date:  2004-09-10       Impact factor: 7.396

10.  Limited relevance of the CHEK2 gene in hereditary breast cancer.

Authors:  Michael R Dufault; Beate Betz; Barbara Wappenschmidt; Wera Hofmann; Katrin Bandick; Astrid Golla; Andrea Pietschmann; Caroline Nestle-Krämling; Kerstin Rhiem; Christine Hüttner; Celia von Lindern; Peter Dall; Marion Kiechle; Michael Untch; Walter Jonat; Alfons Meindl; Siegfried Scherneck; Dieter Niederacher; Rita K Schmutzler; Norbert Arnold
Journal:  Int J Cancer       Date:  2004-06-20       Impact factor: 7.396

View more
  28 in total

1.  Double-strand break damage and associated DNA repair genes predispose smokers to gene methylation.

Authors:  Shuguang Leng; Christine A Stidley; Randy Willink; Amanda Bernauer; Kieu Do; Maria A Picchi; Xin Sheng; Melissa A Frasco; David Van Den Berg; Frank D Gilliland; Christopher Zima; Richard E Crowell; Steven A Belinsky
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

Review 2.  DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.

Authors:  S Solier; Y-W Zhang; A Ballestrero; Y Pommier; G Zoppoli
Journal:  Curr Cancer Drug Targets       Date:  2012-05       Impact factor: 3.428

3.  The risk of gastric cancer in carriers of CHEK2 mutations.

Authors:  Urszula Teodorczyk; Cezary Cybulski; Dominika Wokołorczyk; Anna Jakubowska; Teresa Starzyńska; Małgorzata Lawniczak; Paweł Domagała; Katarzyna Ferenc; Krzysztof Marlicz; Zbigniew Banaszkiewicz; Rafał Wiśniowski; Steven A Narod; Jan Lubiński
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

4.  Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations.

Authors:  Bella Kaufman; Yael Laitman; Jacek Gronwald; Robert Winqvist; Arvids Irmejs; Jan Lubinski; Katri Pylkäs; Janis Gardovskis; Edvins Miklasevics; Eitan Friedman
Journal:  Fam Cancer       Date:  2009-07-17       Impact factor: 2.375

5.  CHEK2*1100delC does not contribute to risk to breast cancer among Malay, Chinese and Indians in Malaysia.

Authors:  Eswary Thirthagiri; Leng San Cheong; Cheng Har Yip; Soo-Hwang Teo
Journal:  Fam Cancer       Date:  2009-04-28       Impact factor: 2.375

Review 6.  Role of CHK2 in cancer development.

Authors:  Rosario Perona; Verónica Moncho-Amor; Rosario Machado-Pinilla; Cristóbal Belda-Iniesta; Isabel Sánchez Pérez
Journal:  Clin Transl Oncol       Date:  2008-09       Impact factor: 3.405

7.  ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancer.

Authors:  Sanna Siltanen; Kirsi Syrjäkoski; Rainer Fagerholm; Tarja Ikonen; Peter Lipman; Jacob Mallott; Kaija Holli; Teuvo L J Tammela; Heikki J Järvinen; Jukka-Pekka Mecklin; Kristiina Aittomäki; Carl Blomqvist; Joan E Bailey-Wilson; Heli Nevanlinna; Lauri A Aaltonen; Johanna Schleutker; Pia Vahteristo
Journal:  Eur J Hum Genet       Date:  2008-03-12       Impact factor: 4.246

Review 8.  Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications.

Authors:  H T Lynch; P M Lynch; S J Lanspa; C L Snyder; J F Lynch; C R Boland
Journal:  Clin Genet       Date:  2009-07       Impact factor: 4.438

9.  Variants in the ATM-CHEK2-BRCA1 axis determine genetic predisposition and clinical presentation of papillary thyroid carcinoma.

Authors:  Anna Wójcicka; Małgorzata Czetwertyńska; Michał Świerniak; Joanna Długosińska; Monika Maciąg; Agnieszka Czajka; Kinga Dymecka; Anna Kubiak; Adam Kot; Rafał Płoski; Albert de la Chapelle; Krystian Jażdżewski
Journal:  Genes Chromosomes Cancer       Date:  2014-03-06       Impact factor: 5.006

10.  Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of origin.

Authors:  Cezary Cybulski
Journal:  Hered Cancer Clin Pract       Date:  2007-09-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.